{"filing":{"accession_number":"0001534120-26-000042","cik":"0001534120","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"avtx-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/avtx-20260616.htm"},"events":[{"id":11196,"run_id":9816,"accession_number":"0001534120-26-000042","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces advancement of AVTX-010, a clinical-stage therapeutic candidate, into development for hidradenitis suppurativa and additional inflammatory disorders. While this represents material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The advancement of a lead candidate into new indications is material to investors assessing the company's pipeline and development strategy, warranting classification as other_material.","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7730,"accession_number":"0001534120-26-000042","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces advancement of AVTX-010, a clinical-stage therapeutic candidate, into development for hidradenitis suppurativa and additional inflammatory disorders. While this represents material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The advancement of a lead candidate into new indications is material to investors assessing the company's pipeline and development strategy, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:19:06.021559+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7730,"accession_number":"0001534120-26-000042","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces advancement of AVTX-010, a clinical-stage therapeutic candidate, into development for hidradenitis suppurativa and additional inflammatory disorders. While this represents material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The advancement of a lead candidate into new indications is material to investors assessing the company's pipeline and development strategy, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T11:19:06.021559+00:00","company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","filing_date":"2026-06-16"}]}